We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WH:NYSEWyndham Hotels & Resorts, Inc. Analysis

Data as of 2026-06-21 - not real-time

$84.20

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Wyndham Hotels & Resorts is trading around $84.2, well above its DCF‑derived fair value of roughly $35, yet analysts see roughly 19% upside and a median price target of $100, suggesting the market may be undervaluing the company’s growth runway. Fundamentals remain robust: operating margin stands near 37%, ROE is an impressive 37.6%, and free cash flow exceeds $340 million, supporting a sustainable 2% dividend with a 66% payout ratio. The recent launch of a native ChatGPT‑powered app and an aggressive Wyndham Rewards promotion could sharpen guest acquisition and boost mid‑scale occupancy, aligning with the company’s high‑margin brand portfolio. Technical signals are supportive—the MACD histogram is positive, the signal line turned bullish, and volume is on an upward trend, while the RSI of 56 indicates the stock is neither overbought nor oversold. However, the lodging sector’s cyclical nature, a 30‑day volatility of 37%, and a beta below 1 point to heightened sensitivity to economic swings, warranting a measured approach.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover with rising volume
  • Neutral RSI indicating balanced momentum
  • Recent AI integration could spark short‑term booking spikes

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong operating and profit margins
  • Forward PE of ~15.7 suggests attractive valuation relative to earnings growth
  • Sustainable dividend and solid free cash flow

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Cyclical exposure of the lodging industry
  • Long‑term brand diversification and global footprint
  • Continued investment in AI‑driven guest experiences

Key Metrics & Analysis

Financial Health

Revenue Growth3.50%
Profit Margin13.40%
P/E Ratio33.4
ROE37.62%
ROA7.59%
Debt/Equity592.84
P/B Ratio14.1
Op. Cash Flow$350.0M
Free Cash Flow$340.0M

Technical Analysis

TrendNeutral
RSI56.6
Support$74.55
Resistance$87.32
MA 20$80.88
MA 50$82.63
MA 200$79.15
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Fair Value$35.17
Target Price$100.18
Upside/Downside18.97%
GradeUndervalued
TypeGrowth
Dividend Yield2.00%

Risk Assessment

Beta0.69
Volatility37.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.